T

    Taysha Gene Therapies Inc (TSHA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.69
    -0.08 (-1.39%)

    Market Cap: $1.88B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    44%(11/25)
    Avg Surprise
    -74.74%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.12
    Range$-0.15 - $-0.09
    5 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.11+6.2%
    60d ago$-0.11+6.2%
    30d ago$-0.12-1.7%
    7d ago$-0.12-1.7%
    Current$-0.12
    Revenue Consensus
    $618180
    Range$0 - $4M
    11 analysts
    Dec 31, 2026
    EPS Consensus$-0.15
    Range$-0.25 - $-0.05
    5 analysts
    Revenue Consensus
    $-244690
    Range$-1994690 - $13M
    12 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.15---
    Sep 26EST
    		-$-0.12---
    Jun 26
    		$-0.13$-0.11-18.18%Miss-62.5%
    Mar 26
    		$-0.11$-0.10-10.00%Miss-37.5%
    Dec 25
    		$-0.07$-0.10+23.43%Beat-4.6%
    Sep 25
    		$-0.09$-0.09+0.00%Beat-28.6%
    Jun 25
    		$-0.08$-0.07-14.29%Miss+11.1%
    Mar 25
    		$-0.08$-0.08+0.00%Beat+20.0%
    Dec 24
    		$-0.07$-0.08+12.50%Beat-107.6%
    Sep 24
    		$-0.07$-0.09+22.22%Beat+92.5%
    Jun 24
    		$-0.09$-0.10+10.00%Beat+76.3%
    Mar 24
    		$-0.10$-0.09-11.11%Miss+64.3%
    Dec 23
    		$0.92$-0.11+936.36%Beat+192.9%
    Sep 23
    		$-0.93$-0.17-447.06%Miss-45.3%
    Jun 23
    		$-0.38$-0.31-22.58%Miss+54.8%
    Mar 23
    		$-0.28$-0.38+26.32%Beat+78.6%
    Dec 22
    		$-0.99$-0.33-200.00%Miss+25.0%
    Sep 22
    		$-0.64$-0.82+21.95%Beat+52.6%
    Jun 22
    		$-0.84$-1.06+20.75%Beat+22.9%
    Mar 22
    		$-1.31$-1.10-19.09%Miss-50.6%
    Dec 21
    		$-1.32$-1.25-5.60%Miss-26.9%
    Sep 21
    		$-1.35$-1.09-23.85%Miss-5.5%
    Jun 21
    		$-1.09$-0.86-26.74%Miss+14.8%
    Mar 21
    		$-0.87$-0.65-33.85%Miss-
    Dec 20
    		$-1.04$-0.37-181.08%Miss-
    Sep 20
    		$-1.28$0.07-1928.57%Miss-
    Jun 20
    		$-1.28$-1.28+0.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-14.11EV/EBITDA-0.61x
    Price/FCF-15.84xFCF Yield-6.31%
    Profitability
    Profit Margin0.00%Operating Margin-2792.00%
    ROE-47.10%ROIC-29.05%
    Financial Health
    Debt/Equity0.13xInterest Coverage-3822.40x
    Current Ratio17.76xQuick Ratio17.76x
    Trading Statistics
    Beta1.19Avg Volume2.59M
    52-Week High$7.3052-Week Low$2.71

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$6.04
    SMA 20$6.18
    SMA 50$6.14
    SMA 200$5.41
    EMA 10$5.98
    EMA 20$6.04
    EMA 50$6.04
    EMA 200$5.33

    MACD

    Line: -0.05Signal: 0.01Hist: -0.06

    ADX

    ADX: 10.8+DI: 16.9-DI: 26.5

    Aroon & PSAR

    Aroon Up44.0
    Aroon Down4.0
    PSAR$6.52

    Bollinger Bands

    Upper Band$6.70
    Lower Band$5.66
    %B Position1679%(Upper)
    Band Width0.03

    RSI (14-Day)

    Neutral
    42.2

    Momentum Oscillators

    Stoch %K17.4
    Stoch %D24.2
    Williams %R-84.3
    ROC (10d)-8.4%
    Momentum-0.52
    CCI (20d)-174.6
    MFI (14d)39.0

    Volatility Measures

    ATR (14d)$0.35(6.1%)
    StdDev (20d)0.26
    Hist Vol60.6%(High)

    Volume Flow

    VWAP$5.67
    OBV199.4M
    AD Line118.4M
    CMF (20d)0.288

    Volume Metrics

    Avg Vol (20d)2.6M
    Vol Ratio0.8x
    VWMA (20d)$6.22

    Pivot Points

    R3$6.21
    R2$6.06
    R1$5.92
    Pivot Point$5.77
    S1$5.63
    S2$5.48
    S3$5.33

    Advanced Oscillators

    TSI-3.59
    Ultimate Osc50.7
    KST8.14

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$5.49M$0$1.99M$2.30M$2.02M$1.79M$1.11M$3.41M$3.60M$4.75M
    Cost of Revenue$0$0$299,000$0$0$0$-625,000$0$0$0$366,000$0
    Gross Profit$0$0$5.49M$0$1.99M$2.30M$2.02M$1.79M$1.11M$3.41M$3.60M$4.75M
    Operating Expenses$47.35M$43.49M$33.78M$34.02M$28.74M$23.72M$21.95M$27.69M$22.41M$27.74M$19.85M$21.00M
    R&D$38.64M$33.81M$24.95M$25.75M$20.14M$15.56M$15.32M$14.95M$15.07M$20.66M$12.68M$11.79M
    SG&A$12.15M$9.68M$8.83M$8.28M$8.60M$8.16M$6.63M$7.90M$7.34M$7.08M$6.72M$8.59M
    Operating Income$-47,349,000$-43,486,000$-28,300,000$-34,024,000$-26,753,000$-21,421,000$-19,932,000$-25,898,000$-21,299,000$-24,330,000$-16,246,000$-16,250,000
    Interest Income$2.33M$2.59M$2.87M$3.17M$1.86M$1.33M$1.70M$2.11M$1.44M$1.69M$1.92M$1.11M
    Interest Expense$6,000$9,000$12,000$15,000$17,000$19,000$22,000$24,000$27,000$29,000$2.11M$1.47M
    Income Before Tax$-46,639,000$-42,410,000$-27,851,000$-32,733,000$-26,882,000$-21,529,000$-18,785,000$-25,524,000$-20,928,000$-24,061,000$47.74M$-117,087,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-46,639,000$-42,410,000$-27,851,000$-32,733,000$-26,882,000$-21,529,000$-18,785,000$-25,524,000$-20,928,000$-24,061,000$47.74M$-117,087,000
    EBITDA$-48,667,000$-44,692,000$-30,410,000$-35,601,000$-28,447,000$-22,553,000$-20,159,000$-27,313,000$-22,019,000$-25,400,000$48.30M$-116,394,000
    EBIT$-48,958,000$-44,987,000$-30,709,000$-35,887,000$-28,724,000$-22,836,000$-20,463,000$-27,607,000$-22,341,000$-25,725,000$47.93M$-116,725,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TSHA

    News

    New Taysha Gene Therapies hires receive 349,000-share stock grant

    Taysha Gene Therapies (Nasdaq: TSHA) announced it granted 349,000 restricted stock units (RSUs) to three new employees on February 2, 2026, as an inducement award under its 2023 Inducement Plan. These RSUs will vest in four equal annual installments, contingent upon continued employment. This move aligns with Nasdaq Listing Rule 5635(c)(4) and is part of the company's strategy to attract and retain talent in the gene therapy sector.

    Stock Titan•8/24/26•
    Somewhat-Bullish

    TSHA-102 Rett Data, Expanded Catalent Deal And New Financing Might Change The Case For Investing In Taysha Gene Therapies (TSHA)

    Taysha Gene Therapies (TSHA) recently reported Q2 2026 results with a net loss of US$46.64 million, but achieved a 100% responder rate in its pivotal TSHA-102 Rett syndrome trials. The company also expanded its manufacturing partnership with Catalent and secured US$230 million in financing, extending its cash runway to late 2028. These developments are expected to significantly reshape the investment outlook for Taysha, as it prepares for potential regulatory filing and commercialization of TSHA-102.

    Simply Wall Street•8/20/26•
    Bullish

    Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call

    Taysha Gene Therapies announced the completion of patient dosing in both the REVEAL pivotal and ASPIRE trials for TSHA-102, a gene therapy for Rett syndrome, with positive longer-term follow-up data showing consistent functional gains. The company has expanded its manufacturing partnership with Catalent and strengthened its financial position with a $230 million financing, extending its cash runway into the second half of 2028. Taysha anticipates reporting top-line data from the REVEAL trial's 6-month interim analysis and receiving FDA feedback on the BLA pathway in the first half of 2027.

    The Globe and Mail•8/19/26•
    Bullish

    Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from Brokerages

    Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has received a consensus "Buy" recommendation from fourteen brokerages, with an average 12-month price target of $12.7692. Several analysts have recently increased their price targets for the stock. Despite missing its last quarterly EPS estimate, the company holds a market capitalization of $2.02 billion and analysts anticipate a -0.51 EPS for the current year.

    MarketBeat•8/18/26•
    Bullish

    RA Capital reports 9.99% TSHA stake in Taysha Gene Therapies (TSHA)

    RA Capital Management and affiliated funds have filed an amended Schedule 13G, disclosing a beneficial ownership of 9.99% in Taysha Gene Therapies (TSHA) common stock as of June 30, 2026. This ownership includes common shares and a portion of pre-funded warrants, capped by a "Beneficial Ownership Blocker" at 9.99%. The filing indicates RA Capital maintains voting and dispositive power over these securities.

    Stock Titan•8/14/26•
    Neutral

    Frequently Asked Questions About TSHA

    Does TSHA pay dividends?
    Taysha Gene Therapies Inc (TSHA) does not currently pay a regular dividend.
    What is TSHA's market cap?
    Taysha Gene Therapies Inc (TSHA) has a market capitalization of $1.88B with a current stock price of $5.69.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In